We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Recommendations from the National Commission into the Regulation of AI in Healthcare, which was established to advise government on a future regulatory framework for AI in healthcare.
Foreword Healthcare is about people. In healthcare we are interested in…
Public Assessment Report on the safety review of the available data on the risk of dementia with the use of bladder anticholinergic medicines.
The Medicines and Healthcare products Regulatory Agency (MHRA) published a review of the safety of albumins manufactured from UK-sourced plasma with respect to variant Creutzfeldt-Jakob disease (vCJD) risk in August 2023. …
A regulator’s view on what the new UK Health Data Research Service must deliver.
Findings from the National Commission into the Regulation of AI in Healthcare's call for evidence and wider research and engagement activities.
MHRA’s Public Sector Equality Duty report 2026 sets out progress on equality, diversity and inclusion across regulation, public engagement and workforce.
Report of the Isotretinoin Implementation Advisory Expert Working Group regarding recommendations to strengthen the safe use of isotretinoin, the acne medicine commonly known by brand names Roaccutane and Reticutan.
Public Assessment Report on the review of the implementation of the recommendations of the Commission on Human Medicines Isotretinoin Expert Working Group and Isotretinoin Implementation Advisory Expert Working Group.
Public Assessment Report on improving information regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs.
Details and statistics on the import of unlicensed medicines from March 2014 onwards.
A research report on attitudes regarding identifying and reporting harms associated with the use of DMHT and awareness of the MHRA Yellow Card Scheme.
Public Assessment Report on the review of risk minimisation for fluoroquinolone antibiotics.
Public Assessment Report on the removal of the indication for post-operative pain for modified-release opioids.
Public Assessment Report on managing reproductive risks in male patients under 55 taking valproate.
Public Assessment Report of review of results of a post-authorisation safety study on paternal exposure to valproate.
Public Assessment Report of review of Topiramate safety data and expert advice on management of risks.
A research report on attitudes to digital mental health technology.
Public Assessment Report of review of Finasteride safety data and expert advice on management of risks.
Public Assessment Report of review of valproate safety data and expert advice on management of risks.
Good clinical practice (GCP) referrals received by the MHRA for 2011 to 2020.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).